Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | PHGDH | O43175 | 11/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19997267 | 0.82 | RXFP1 (0.59) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL3587743 | 0.81 | MCL1 (0.59) | PHGDHMEN1KMT2A | |
| SCHEMBL2643465 | 0.80 | RXFP1 (0.60) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL17324809 | 0.77 | RXFP1 (0.64) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL43328 | 0.77 | KDM4E (0.66) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL3591526 | 0.77 | L3MBTL1 (0.49) | MEN1KMT2A | |
| SCHEMBL10003854 | 0.76 | PPARG (0.56) | — | |
| SCHEMBL13415456 | 0.76 | RXFP1 (0.62) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL718533 | 0.76 | RXFP1 (0.52) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL24198804 | 0.74 | RXFP1 (0.59) | RXFP1PHGDHMEN1KMT2AAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| EP-1937663-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | Inpharmatica Limited (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007036730-A9 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LTD (GB) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007036730-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | PPARG, PPARD, PPARA | RXFP1 1090/4885PHGDH 1559/4885MEN1 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.